The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Grant | Alive

Total Raised


Last Raised

$870K | 1 yr ago

About Fujirebio

Fujirebio, fka Innogenetics, conceives, develops, produces and markets in vitro diagnostics (IVD) testing solutions.

Fujirebio Headquarter Location

Technologiepark 6

Ghent, 9052,


+32 9 329 13 29

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Fujirebio Patents

Fujirebio has filed 74 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Breast cancer
  • Gynaecological cancer
patents chart

Application Date

Grant Date


Related Topics




Inflammations, Digestive system, Autoimmune diseases, Rare diseases, Digestive system surgery


Application Date


Grant Date



Related Topics

Inflammations, Digestive system, Autoimmune diseases, Rare diseases, Digestive system surgery



Latest Fujirebio News

  • When was Fujirebio founded?

    Fujirebio was founded in 1985.

  • Where is Fujirebio's headquarters?

    Fujirebio's headquarters is located at Technologiepark 6, Ghent.

  • What is Fujirebio's latest funding round?

    Fujirebio's latest funding round is Grant.

  • How much did Fujirebio raise?

    Fujirebio raised a total of $870K.

  • Who are the investors of Fujirebio?

    Investors of Fujirebio include Vlaams Innovatiefonds, Capricorn Partners and Alta Berkeley.

  • Who are Fujirebio's competitors?

    Competitors of Fujirebio include Acumen Pharmaceuticals, Euroclone SpA, DermTech International, RevDia, CellXplore and 11 more.

You May Also Like

IDEXX Laboratories

IDEXX Laboratories is a provider in pet healthcare, serving practicing veterinarians around the world with a range of diagnostic and information technology-based products and services. IDEXX is also a worldwide provider of livestock and poultry diagnostic tests and tests for the quality and safety of water and milk.


CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.


Onconix, Inc. is an intellectual property, biotechnology company focused on identifying and marketing diagnostic technologies from various research settings, which have undergone peer review. Currently, Onconix has exclusive rights to market and develop promising new tests for cervical cancer.


RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.


ARCXIS develops, produces and distributes portable biological real-time diagnostic tools with the ability to analyze, detect, and characterize infectious disease agents. Arcxis Biotechnologies develops rapid diagnostic tools for use in national defense, clinical diagnostic, as well as food and beverage applications. The company was founded in 2004 and is based in Houston, Texas.

Proteome Systems

Tyrian Diagnostics is a biotechnology company that specialises in the discovery of biomarkers of disease and in diagnostic test development. The company are building a strong intellectual property portfolio to develop a pipeline of diagnostic products and establishing commercial partnerships to maximise market share and revenue generation from these products. One key avenue for commercialisation is the application of biomarkers to the company's point of need test platform, DiagnostIQTM.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.